Clinical Trials Directory
We are doing this study to find out if an investigational drug called HM43239 (the study drug) is a safe and effective option for people who have AML that came back after remission or did not respond to standard treatments. We also want to find out what dose of the study drug works best for most patients.
If you decide to participate in this study, you will have a screening visit to see if you meet the criteria to be included in this study. If you are eligible, you will proceed to the study drug period. During this period, you will:
- Take the study drug tablets by mouth at about the same time each morning and within 30 minutes of finishing your breakfast for the first 15 days
- After the first 15 days, continue to take the study drug by mouth at approximately the same time every day, within 30 minutes of finishing a meal (breakfast, lunch, or dinner) of your choice
- Blood draws
- Imaging tests (CT, PET/CT and MRI)
- ECG
We are doing this study to compare two different treatment options for mantle cell lymphoma. We want to find out which option has the best outcomes for older adults. We will compare the results of continuous treatment with zanubritinib to treatment with zanubrutinib that is stopped after the initial six 28-day cycles of chemotherapy and restarted only if your disease gets worse following the initial six 28-day cycles of chemotherapy.
We are doing this study to see if combining immunotherapy with chemotherapy is a better treatment than chemotherapy alone for NSCLC.
We are doing this study to help create a national biobank of samples and data about patients who experience side effects when they take immunotherapy drugs for their cancer. We want to find out why some people experience side effects and why others do not. We also want to learn more about how to diagnose and treat these side effects more effectively.